On-demand drug release using magneto-electric nanoparticles

Patent metadata

Field	Value
Publication number	US-9724503-B2
Application number	US-201514703521-A
Country	US
Kind code	B2
Filing date	May 4, 2015
Priority date	Nov 6, 2012
Publication date	Aug 8, 2017
Grant date	Aug 8, 2017

Abstract

Disclosed herein are methods of delivering drugs to a subject in a controlled release fashion by administering a magneto-electric nanoparticle having ionic bonds to a drug then applying a magnetic field to weaken the ionic bonds and release the drug.

First claim

What is claimed:

1. A method of treating a subject, comprising:
administering to the subject a plurality of magneto-electric nanoparticles (MENP) having a drug associated thereto; and
applying a magnetic field to the subject to generate electric fields on membranes of cells to which the plurality of MENP are adjacent such that the magnetic field strength is sufficient to generate an electric field capable of causing nano-electroporation sites to develop on targeted disease cells but not strong enough to cause nano-electroporation sites on other cells.

2. The method of claim 1 , wherein the strength of the magnetic field is increased after nano-electroporation sites are formed on the targeted disease cells in order to release the drug from the plurality of MENP.

3. The method of claim 1 , wherein each of the plurality of MENP further comprise a biomarker-specific antibody.

4. The method of claim 1 , wherein the drug is an anti-neoplastic drug.

5. The method of claim 1 , wherein the disease cells comprise cancer cells.

6. The method of claim 2 , wherein the strength of the magnetic field to cause nano-electroporation sites to develop on targeted disease cells, has a value denoted by H th , and the strength of the magnetic field in order to release the drug from the MENP, has a value denoted by Hr, and Hr>H th , wherein H th is determined by electric properties of cell membrane of the targeted disease cells that lead to localized electroporation effects.

7. The method of claim 6 , further comprising adding intermediate layers or coatings between the drug and the MENP to control the Hr.

8. The method of claim 7 , wherein Hr has a value between 10 Oe to 200 Oe.

9. The method of claim 1 , wherein the magnetic field directs the plurality of MENP adjacent to the targeted disease cells.

10. A method as defined in claim 1 , wherein the magnetic field comprises a direct current (DC) field.

11. A method as defined in claim 1 , wherein the plurality of MENP comprise CoFe 2 O 4 @BaTiO 3 .

12. A method for treating diseased cells in a human subject, comprising:
administering to the subject a plurality of magneto-electric nanoparticles (MENP) having a drug associated thereto;
applying a magnetic field to the subject to generate electric fields on membranes of cells to which the plurality of MENP are adjacent whereas the strength of the magnetic field is such that it generates an electric field strong enough to cause nano-electroporation sites to develop on the targeted disease cells but not strong enough to cause nano-electroporation sites on other cells; and
applying a magnetic field equal to or greater than a release field threshold after nano-electroporation sites have developed in order to release the drug from the plurality of MENPs.

13. A method as defined in claim 12 , wherein the magnetic field used to develop the nano-electroporation sites on the targeted disease cells comprises a direct current (DC) field.

14. A method as defined in claim 13 , wherein the magnetic field used to release the drug from the MENP comprises an alternating current (AC) field.

15. A method as defined in claim 12 , wherein the magnetic field used to release the drug from the MENP comprises an alternating field.

16. A method as defined in claim 12 , where the magnetic field used to release the drug from the MENP is stronger than the magnetic field for nano-electroporation.

Assignees

• Univ Florida Int
• Liang Ping

Inventors

• Khizroev Sakhrat
• Guduru Rakesh
• Liang Ping

Classifications

• A61N1/327

  for enhancing the absorption properties of tissue, e.g. by electroporation · CPC title

• A61K9/0009

  involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis · CPC title

• A61K47/6943

  the form being a pill, a tablet, a lozenge or a capsule · CPC title

• A61K9/5094

  Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting · CPC title

• A61P35/00

  Antineoplastic agents · CPC title